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Background: Reduced-intensity conditioning (RIC) provides
graft-versus-disease effect with less treatment related
toxicity, making allogeneic hematopoietic stem cell trans-
plantation (HSCT) available to more recipients. The objective
was to describe the etiology and spectrum of non-relapse
mortality (NRM) following RIC HSCT for myeloid neoplasms.
Methods: After due IRB approval, consecutive patients, who
underwent RIC HSCT for myeloid neoplasms between 2000
and 2014 at Mayo Clinic, Rochester were identiﬁed. RIC
regimens were melphalan/ﬂudarabine or busulfan/ﬂudar-
abine. Graft-versus-host disease (GVHD) prophylaxis was per
institutional standards. Cause of mortality was retrospec-
tively analyzed through clinical documentation.
Results: 200 patients, 125 (63%) males, median age 60
(range, 18 to 72) underwent RIC HSCT for myeloid neoplasms
(AML, 59% [77% in CR]; MDS, 30% [52%without excess blasts];
myeloﬁbrosis, 7.5%; and CML 3.5%). At last follow-up, 102
(51%) patients had died. Median follow-up was 14 months
(range, 0-111). Of the 102 patients, 41 (40%) patients had
disease relapse (AML, 28 [61% in prior CR]; MDS, 11[72% with
prior excess blasts]); and myeloﬁbrosis, 2 (5%).
NRM was documented in 59 (58%) of 102 patients that
had died and 2 patients were lost to follow-up. In 54 (92%) of
the 59 patients, death was attributed to transplant-related
complications (sepsis, 11 [20%]; multiple organ dysfunction
syndrome (MODS) and sepsis, 10 [19%]; respiratory failure
secondary to infection, 5 [9%]; acute GVHD, 9 [17%]; chronicFigure 1GVHD, 12 [22%]; intracranial hemorrhage from thrombocy-
topenia, 4 [7%]; diffuse alveolar hemorrhage, 2 [4%]; and graft
failure, 1 [2%]). Amongst acute GVHD deaths (67% grade 4- all
GI GVHD), CMV infection and steroid-induced myopathy
contributed to death. In patients with chronic GVHD (83%
severe), associated causes of death included respiratory
failure from obliterative bronchiolitis, encephalopathy, and
MODS from transplant-associated microangiopathy.
The remaining 5 NRM patients died of non-transplant
related complications; unrelated malignancies (4) and trau-
matic intracranial hemorrhage (1).
Conclusion: Although RIC increases access to transplant for
otherwise ineligible patients, it still poses signiﬁcant mor-
tality risk from disease relapse (20%) and transplant-related
complications (27%). No cases of sinusoidal obstruction
syndrome were seen in our series.517
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Background: CAR modiﬁed T-cell therapy is an engineered
immunotherapy that harnesses the power of the patient’s
immune system to ﬁght cancer. Although trials in this ther-
apy have been small to date, encouraging results have been
reported from phase I trials in acute lymphoblastic leukemia
and chronic lymphocytic leukemia.
Poor risk relapsed or refractory diffuse large B cell lym-
phoma (rel/ref DLBCL) is a novel area of investigation for the
use of CAR T-cell therapy. It is hypothesized that cellular
therapy can be optimized by giving CAR T-cells immediately.
